Ipilimumab: all 592 studies that test it

Page 6 of 6. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.

• Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasCompletedNCT02829931Phase 1
• Ipilimumab for Head and Neck Cancer PatientsActive, not recruitingNCT02812524Phase 1
• Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsCompletedNCT02716272Phase 2
• Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02703623Phase 2
• Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerActive, not recruitingNCT02696993Phase 1/2
• Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasTerminatedNCT02675439Phase 1
• Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesTerminatedNCT02668770Phase 1
• Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain MetastasesCompletedNCT02662725Phase 2
• Sequential Combo Immuno and Target Therapy (SECOMBIT) StudyCompletedNCT02631447Phase 2
• Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaCompletedNCT02626962Phase 2
• A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma PatientsStatus unknownNCT02608437Phase 1
• Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic SyndromeActive, not recruitingNCT02530463Phase 2
• Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NEDCompletedNCT02523313Phase 2
• A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid TumorsCompletedNCT02516527Phase 1
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1
• A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisStatus unknownNCT02460068Phase 3
• Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02453620Phase 1
• Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced MelanomaWithdrawnNCT02452281Phase 1/2
• Phase I Clinical Trial of Cryoimmunotherapy Against Prostate CancerCompletedNCT02423928Phase 1
• A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedNCT02413827Phase 1/2
• Trial of SBRT With Concurrent Ipilimumab in Metastatic MelanomaCompletedNCT02406183Phase 1
• Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedNCT02381314Phase 1
• Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain MetastasesActive, not recruitingNCT02374242Phase 2
• Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT02311920Phase 1
• Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)CompletedNCT02307149Phase 1
• Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant MelanomaCompletedNCT02275416Phase 1/2
• A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic MelanomaCompletedNCT02272855Phase 2
• Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid TumorsCompletedNCT02239900Phase 1
• Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by SurgeryActive, not recruitingNCT02210117Early Phase 1
• Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV MelanomaTerminatedNCT02200562Phase 1
• A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02174172Phase 1
• Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity MelanomaCompletedNCT02115243Phase 1
• T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate CancerCompletedNCT02113657Early Phase 1
• Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases MelanomaCompletedNCT02094391Phase 2
• A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.Active, not recruitingNCT02068196Phase 4
• Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung CancerCompletedNCT01998126Phase 1
• Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma PatientsTerminatedNCT01988077Phase 2
• LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabCompletedNCT01986426Phase 1
• SRS (Stereotactic Radiosurgery) Plus IpilimumabTerminatedNCT01950195Phase 1
• Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck CancerCompletedNCT01935921Phase 1
• Study of the Drug Ipilimumab for Metastatic Merkel Cell CarcinomaWithdrawnNCT01913691Phase 2
• Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT01896999Phase 1/2
• Sipuleucel-T and Ipilimumab for Advanced Prostate CancerCompletedNCT01832870Phase 1
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
• Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01757639Phase 1
• Ipilimumab and Lenalidomide in Advanced CancerCompletedNCT01750983Phase 1
• Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorCompletedNCT01750580Phase 1
• Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic MelanomaCompletedNCT01743157Phase 1/2
• Ipilimumab and Imatinib Mesylate in Advanced CancerCompletedNCT01738139Phase 1
• Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver MetastasesTerminatedNCT01730157Early Phase 1
• Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
• Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical CancerCompletedNCT01711515Phase 1
• Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic MelanomaWithdrawnNCT01689870Phase 1/2
• Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT01688492Phase 1/2
• Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV MelanomaActive, not recruitingNCT01676649Phase 2
• A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic MelanomaCompletedNCT01654692Phase 2
• Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are MetastaticCompletedNCT01643278Phase 1
• Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for MelanomaCompletedNCT01608594Phase 1
• A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaTerminatedNCT01604889Phase 1/2
• Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable MelanomaStatus unknownNCT01565837Phase 2
• Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant MelanomaTerminatedNCT01557114Phase 1
• Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast CancerCompletedNCT01502592Phase 1
• A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2CompletedNCT01480323Phase 2
• Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant CancerCompletedNCT01445379Phase 1
• IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic MelanomaWithdrawnNCT01409187Phase 1/2
• IPI Biochemotherapy for Chemonaive Patients With Metastatic MelanomaTerminatedNCT01409174Phase 1
• Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in MelanomaCompletedNCT01363206Phase 2
• THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced DiseaseCompletedNCT01355120Phase 2
• The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung CancerCompletedNCT01331525Phase 2
• Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced MelanomaCompletedNCT01245556Phase 1
• Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1CompletedNCT01216696Phase 2
• Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV MelanomaCompletedNCT01176474Phase 1
• Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for MelanomaCompletedNCT00972933Early Phase 1
• Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedNCT00871481Phase 1/2
• Combination of Anti-CD137 & Ipilimumab in Patients With MelanomaWithdrawnNCT00803374Phase 1
• Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaWithdrawnNCT00732186Phase 1
• Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT00729950Phase 1
• CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLLActive, not recruitingNCT00586391Phase 1
• Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical ResectionCompletedNCT00362713Phase 1
• Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaWithdrawnNCT00357461Phase 2
• Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289640Phase 2
• A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCompletedNCT00289627Phase 2
• Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)CompletedNCT00261365Phase 1/2
• A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideCompletedNCT00135408Phase 2
• Study of MDX-010 in Stage IV Breast CancerCompletedNCT00083278Phase 2
• Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate CancerCompletedNCT00064129Phase 1
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell CancerCompletedNCT00057889Phase 2
• Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate CancerCompletedNCT00050596Phase 2
• Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic MelanomaCompletedNCT00050102Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine TherapyCompletedNCT00047164Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1

← Ipilimumab overview